Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1，Randomized, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered LT-002-158 in Healthy Adult Volunteers

NCT06082323 is registered in ClinicalTrials.gov with Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. as lead sponsor.

NCT NCT06082323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06082323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1，Randomized, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered LT-002-158 in Healthy Adult Volunteers
Lead sponsor
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 13, 2024
Completion date
November 25, 2025
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, healthy volunteer, hidradenitis suppurativa